22 May 2026
EMA/CVMP/106114/2026
Committee for Veterinary Medicinal Products

Summary of opinion[1] (initial authorisation)

Nobivac NXT HCPCh

Common name: Feline calicivirosis, feline rhinotracheitis, feline panleucopenia and feline chlamydiosis (live) vaccine

On 21 May 2026, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion[2], recommending the granting of a marketing authorisation for the veterinary medicinal product Nobivac NXT HCPCh, lyophilisate and solvent for suspension for injection, intended for cat. The applicant for this veterinary medicinal product is Intervet International B.V.

Nobivac NXT HCPCh is an immunological veterinary medicinal product (vaccine) containing feline herpesvirus 1, strain G2620A (live), feline calicivirus, strain F9 (live), feline panleucopenia virus, strain MW-1 (live) and *Chlamydia felis*, strain Baker (live) as the active substances.

The benefits of Nobivac NXT HCPCh are its efficacy for the active immunisation of cats:

- to reduce mortality, clinical signs and virus excretion caused by infection with feline herpesvirus type 1 (FHV);
– to reduce clinical signs and virus excretion caused by infection with feline calicivirus (FCV);
– to prevent mortality, clinical signs, leucopenia and virus excretion caused by infection with feline panleucopenia virus (FPL);
– to reduce clinical signs and bacterial excretion caused by infection with *Chlamydia felis*;

The onset of immunity is 1 week. The duration of immunity is 1 year after primary vaccination or 3 years after re-vaccination for FHV and FCV; 3 years for FPL and 1 year for *Chlamydia felis.*

Nobivac NXT HCPCh is generally well tolerated at the recommended dose. The most common side effects are injection site swelling and elevated temperature (common). Limping is observed very rarely.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Commission.

The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Nobivac NXT HCPCh and therefore recommends the granting of the marketing authorisation.